Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozanimod - Celgene Corporation

Drug Profile

Ozanimod - Celgene Corporation

Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIA

Latest Information Update: 26 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
  • Class Amines; Anti-inflammatories; Antivirals; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Ulcerative colitis
  • Phase III Crohn's disease
  • Phase II COVID 2019 infections

Most Recent Events

  • 10 May 2024 Celgene plans a phase III trial for Multiple Sclerosis (In-children, In-adolescents, Treatment-experienced) in the USA (PO) (NCT06408259)
  • 13 Apr 2024 Efficacy data from a phase III ENLIGHTEN trial in Multiple sclerosis presented at the 76th Annual Meeting of the American Academy of Neurology 2024 (AAN-2024)
  • 29 Feb 2024 Updated efficacy data from a phase III ENLIGHTEN trial in Multiple sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 (ACTRIMS-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top